Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical study of SPC-069

X
Trial Profile

A phase I clinical study of SPC-069

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPC-069 (Primary)
  • Indications Respiratory tract infections
  • Focus Adverse reactions; First in man
  • Sponsors SpectrumX
  • Most Recent Events

    • 20 Sep 2022 According to a SpectrumX media release, the trial is expected to be launched in March 2023, subject to necessary regulatory and ethics committee approvals.
    • 20 Sep 2022 According to a SpectrumX media release, the company has signed a start-up agreement with an experienced leader with a strong background in conducting human challenge trials in infectious and respiratory diseases, to support the Company in the design and execution of this trial. It will remain anonymous until after clinical trial agreement, which SpectrumX anticipates happening in due course after its Scientific Advisory Meeting with the MHRA on 14 Nov 2022.
    • 13 Sep 2022 According to a Spectrum Antimicrobials media release, the investment into the facility provides a significant launchpad to start this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top